New Zealand markets closed

OCGN Jan 2025 0.500 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.5700+0.0700 (+14.00%)
As of 12:01PM EDT. Market open.
Full screen
Previous close0.5000
Open0.5500
Bid0.3000
Ask0.6000
Strike0.50
Expiry date2025-01-17
Day's range0.5500 - 0.6000
Contract rangeN/A
Volume5
Open interest4.71k
  • GlobeNewswire

    Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa

    MALVERN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen will present at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024 at the Arizona Biltmore in Phoenix, AZ. “The Cell & Gene Meeting on the Mesa convenes

  • GlobeNewswire

    Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference

    MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan’s 8th Annual Genetic Medicines Conference being h

  • GlobeNewswire

    Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop

    MALVERN, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-founder of Ocugen, will speak during the workshop titled, “U.S.-India Biotechnology Cooperation: Realizing Benefits, Reducing Risks.” This two-day event will take place from September